Andere Sprachen Vaxxinity, Inc.

Aktien

A3C7GC

US92244V1044

VAXX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
0,1166 ^USD	-3,95 %		-75,51 %	-86,28 %

27.03.	Vaxxinity, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
07.03.	Vaxxinity gibt positive Daten aus klinischer Phase-1-Studie für Parkinson-Krankheit auf der AD/PD? bekannt 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Advance Premarket Monday	22.04.
Sector Update: Health Care	22.04.
Vaxxinity Issues Shareholder Letter	20.04.
Vaxxinity Issues Shareholder Letter	20.04.
Vaxxinity to Voluntarily Delist From Nasdaq; Shares Sink After Hours	19.04.
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock	19.04.
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting	28.03.
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates	27.03.
Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
North American Morning Briefing : Tech in Focus on -2-	25.03.
Vaxxinity : UB-312 Target Engagement - ADPD 2024	12.03.
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024	07.03.
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson?s Disease at AD/PD? 2024	07.03.
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published	15.02.
Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies	15.02.
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024	13.02.
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024	13.02.
Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders	13.02.
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	30.01.
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	30.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vaxxinity, Inc.

Aktien

A3C7GC

US92244V1044

VAXX

Andere Sprachen

Filter